China Drug Approvals | iPharmaCenter

Vyloytm (zolbetuximab) Gains Approval in China for First-Line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | iPharmaCenter

China’s National Medical Products Administration (NMPA) has approved Vyloytm (zolbetuximab) for use alongside fluoropyrimidine- and...

Nucala has become the first anti-interleukin-5 therapy approved in China for treating adults with chronic rhinosinusitis with nasal...

HUTCHMED and Innovent Biologics have announced that the China National Medical Products Administration (NMPA) has conditionally approved...

HUTCHMED has announced that the China National Healthcare Security Administration (NHSA) has renewed the inclusion of savolitinib in the...

The 2024 National Reimbursement Drug List (NRDL) unveiled by China's National Healthcare Security Administration adds 91 new drugs,...

AstraZeneca and Daiichi Sankyo’s drug, Enhertu (trastuzumab deruxtecan), have been granted conditional approval in China as a treatment...

China’s National Medical Products Administration (NMPA) has officially approved Padcev (enfortumab vedotin) for the treatment of adult...

Enhertu, developed by AstraZeneca and Daiichi Sankyo, has gained conditional approval in China for use in patients with advanced or...

HUTCHMED (China) Limited has announced that the New Drug Application (NDA) for tazemetostat, aimed at treating adult patients with...

Eisai and Biogen announced that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody, Leqembi (ecanemab) (known in...

China’s National Medical Products Administration (NMPA) has granted approval for AstraZeneca’s Tagrisso (osimertinib), combined with...

May 13, 2024 Eisai's Fycompa was approved for generalized tonic-clonic seizures Approved in China for the supplementary management of...

December 21, 2023 Takeda's Livtencity was approved in China for CMV infections Takeda declares the approval from China NMPA for...

Takeda announced that the National Medical Products Administration (NMPA) of China approved Exkivity (mobocertinib) for treating adults...

December 23, 2022 Eisai initiated data submission for BLA of lecanemab in China for Alzheimer's Eisai and Biogen announced that they have...